ES2027013T3 - Un procedimiento para preparar una forma de dosificacion de liberacion controlada. - Google Patents

Un procedimiento para preparar una forma de dosificacion de liberacion controlada.

Info

Publication number
ES2027013T3
ES2027013T3 ES198888310271T ES88310271T ES2027013T3 ES 2027013 T3 ES2027013 T3 ES 2027013T3 ES 198888310271 T ES198888310271 T ES 198888310271T ES 88310271 T ES88310271 T ES 88310271T ES 2027013 T3 ES2027013 T3 ES 2027013T3
Authority
ES
Spain
Prior art keywords
dosage form
controlled release
release dosage
medicinal product
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888310271T
Other languages
English (en)
Inventor
Masayoshi Samejima
Kazuo Noda
Masao Kobayashi
Shigeyuki Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2027013T3 publication Critical patent/ES2027013T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMA DE DOSIFICACION DE LIBERACION CONTROLADA QUE CONSISTE ESENCIALMENTE EN UN NUCLEO QUE CONTIENE UN MEDICAMENTO, UN FORRO INTERIOR EN CAPAS COMPUESTO DE ETILCELULOSA Y UNA SUSTANCIA HIDROFOBICA, Y UN FORRO EXTERNO EN CAPAS QUE CONTIENE UN MEDICAMENTO SE DESCRIBE. DICHA FORMA DE DOSIFICACION MUESTRA UNA RAPIDA ELEVACION DE LA CONCETRACION EN SANGRE DEL MEDICAMENTO Y AL MISMO TIEMPO MANTIENE LOS ALTOS NIVELES EN LA CONCENTRACION SANGUINEA DURANTE UN PROLONGADO PERIODO DE TIEMPO.
ES198888310271T 1987-11-06 1988-11-01 Un procedimiento para preparar una forma de dosificacion de liberacion controlada. Expired - Lifetime ES2027013T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28118987 1987-11-06

Publications (1)

Publication Number Publication Date
ES2027013T3 true ES2027013T3 (es) 1992-05-16

Family

ID=17635585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888310271T Expired - Lifetime ES2027013T3 (es) 1987-11-06 1988-11-01 Un procedimiento para preparar una forma de dosificacion de liberacion controlada.

Country Status (24)

Country Link
US (1) US4963365A (es)
EP (1) EP0315414B1 (es)
KR (1) KR940002655B1 (es)
CN (1) CN1035099C (es)
AT (1) ATE68343T1 (es)
AU (1) AU610275B2 (es)
BG (1) BG60638B1 (es)
CA (1) CA1331565C (es)
DE (1) DE3865631D1 (es)
DK (1) DK175249B1 (es)
ES (1) ES2027013T3 (es)
FI (1) FI96273C (es)
FR (1) FR2622799B1 (es)
GR (1) GR3002915T3 (es)
HK (1) HK44593A (es)
HU (1) HU201468B (es)
IE (1) IE60785B1 (es)
IL (1) IL88083A (es)
NO (1) NO176233C (es)
PH (1) PH25905A (es)
PT (1) PT88945B (es)
RU (1) RU1816213C (es)
SG (1) SG15493G (es)
ZA (1) ZA888147B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
DE59000232D1 (de) * 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
CA2030516C (en) * 1989-03-22 2000-10-10 Toyoji Kaneko Parathyroid hypertensive factor
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
EP0585355B1 (en) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
DE69327745T2 (de) * 1992-05-29 2000-09-21 Nikken Chemicals Co., Ltd. Tablette zur langsamen Freisetzung von Natriumvalproat
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
DE69732983T2 (de) * 1996-09-13 2006-02-16 Shionogi & Co., Ltd. Zubereitung mit verlängerter freisetzung unter verwendung einer thermischen umwandlung sowie verfahren zu deren herstellung
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000009133A1 (fr) * 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN1296046C (zh) * 2003-12-23 2007-01-24 广州市医药工业研究所 盐酸地尔硫䓬控释胶囊剂及其制备方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5649784B2 (ja) 2006-02-07 2015-01-07 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 組成物、基材を組成物でコーティングする方法、被覆基材、製品、フィルム、ペレット、タブレット及びカプセル
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) * 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) * 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CN102805733B (zh) * 2011-06-01 2016-03-09 日东电工株式会社 颗粒制剂及其制造方法
FR2996418B1 (fr) * 2012-10-09 2015-05-29 Seppic Sa Compositions alimentaires comprenant des capsules obtenues par coacervation ne mettant pas en œuvre de reticulant toxique
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
BR112022017700A2 (pt) * 2020-03-02 2023-01-17 Gruenenthal Gmbh Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1172087A (fr) * 1956-01-25 1959-02-05 Bellon Labor Sa Roger Perfectionnements concernant l'enrobage de préparations à effet retardé et à effet soutenu
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
IT1153487B (it) * 1982-04-15 1987-01-14 Prophin Lab Spa Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
US4390406A (en) * 1982-07-23 1983-06-28 Allied Corporation Replaceable outer junction double junction reference electrode
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins

Also Published As

Publication number Publication date
SG15493G (en) 1993-04-16
IL88083A (en) 1992-11-15
CA1331565C (en) 1994-08-23
FR2622799B1 (fr) 1991-11-29
NO884947D0 (no) 1988-11-04
GR3002915T3 (en) 1993-01-25
PT88945A (pt) 1989-11-30
HK44593A (en) 1993-05-14
CN1035099C (zh) 1997-06-11
EP0315414B1 (en) 1991-10-16
KR890007720A (ko) 1989-07-05
US4963365A (en) 1990-10-16
FR2622799A1 (fr) 1989-05-12
PH25905A (en) 1991-12-19
IL88083A0 (en) 1989-06-30
FI96273C (fi) 1996-06-10
FI885101L (fi) 1989-05-07
HU201468B (en) 1990-11-28
AU2472788A (en) 1989-05-11
FI96273B (fi) 1996-02-29
KR940002655B1 (ko) 1994-03-28
NO884947L (no) 1989-05-08
IE883246L (en) 1989-05-06
CN1033007A (zh) 1989-05-24
BG60638B1 (bg) 1995-11-30
ZA888147B (en) 1990-06-27
RU1816213C (ru) 1993-05-15
PT88945B (pt) 1993-05-31
DK618088A (da) 1989-05-07
NO176233B (no) 1994-11-21
BG85941A (bg) 1993-12-24
FI885101A0 (fi) 1988-11-04
DE3865631D1 (de) 1991-11-21
IE60785B1 (en) 1994-08-10
AU610275B2 (en) 1991-05-16
NO176233C (no) 1995-03-01
ATE68343T1 (de) 1991-11-15
HUT50624A (en) 1990-03-28
EP0315414A1 (en) 1989-05-10
DK618088D0 (da) 1988-11-04
DK175249B1 (da) 2004-07-19

Similar Documents

Publication Publication Date Title
ES2027013T3 (es) Un procedimiento para preparar una forma de dosificacion de liberacion controlada.
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
ES2053678T3 (es) Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
ATE9695T1 (de) Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DK28480A (da) Fremgangsmaade til fremstilling af tabletter med forsinket frigivelse af det aktive middel i hvilke tabletter frigivelseshastigheden for det aktive middel er fastlagt i forvejen
NO157212C (no) Fremgangsmaate for fremstilling av belegg med lav emisjonsevne.
BE878883A (fr) Implant de delivrance de medicament pouvant etre enleve
NO163693C (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser av platina.
JPS57131721A (en) Drug treatment for body disease
JPS56156141A (en) Ultrasonic tomogram projection apparatus for body cavity
DE3370476D1 (en) Tetramethacrylic or tetraacrylic acid compounds and their use
JPS55166142A (en) Capsule device for medical treatment
NO160511C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklo-butanderivater.
NO830900L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske derivater.
NO168478C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive vinylthioacetamido-oxacefalosporinderivater.
DK313281A (da) Anordning til indgift af medicinsk aktive substanser
ATE37871T1 (de) Substituierte azabicycloalkane, ihre verwendung, pharmazeutische praeparate, welche diese verbindungen enthalten, und verfahren zur herstellung dieser verbindungen.
IT8167585A0 (it) Composto chimico utilizzabile parti colarmente come agente farmaceutico antiulcera e procedimento per lasua fabbricazione
NO160001C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive spiro-3-hetero-azolon-derivater.
NO801989L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidopyrimidiner
NO159590C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive fenyleddiksyre-derivater.
MY103627A (en) A controlled release pharmaceutical dosage form and a process for preparing same.
ATA690679A (de) In den koerper implantierbare einrichtung zur konstanten abgabe eines wirkstoffs
NO160139C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive akridanonderivater.
IT8367887A0 (it) Procedimento per iniettare sostanze medicinali e contenitore di medicinali per l attuazione del procedimento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 315414

Country of ref document: ES